The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

BACKGROUND: Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR. The difficulties in obtaining biopsies at progression make it challenging to in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Demuth, Christina, Madsen, Anne Tranberg, Weber, Britta, Wu, Lin, Meldgaard, Peter, Sorensen, Boe Sandahl
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815238/
https://ncbi.nlm.nih.gov/pubmed/29448920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4108-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky